Skip to content

Bile duct cancer · 56 slides

Cholangiocarcinoma.

Follow two cases of malignant obstruction to see how the tumour's location shapes staging, drainage and treatment.

About the downloads

PowerPoint without speaker notes. SHA-256 checksums verify the downloaded files.

Contents · 11 parts

Opening cases

Slide 1: Cholangiocarcinoma
01 / 56

Cholangiocarcinoma

HEPATOBILIARY SURGERY · LECTURE 10

Dr Prateek Gupta

Assistant Professor, Department of General Surgery Dayanand Medical College & Hospital, Ludhiana prateekguptasurgery.com

Slide 2: Two patients, one cancer
02 / 56

Two patients, one cancer

TWO PATIENTS

A · A man in his sixties

Painless jaundice, itching and weight loss. The scan shows dilated ducts inside the liver on both sides and a collapsed gallbladder.

B · A woman in her seventies

Painless jaundice, dark urine and pale stools. Her gallbladder can be felt. The scan shows dilated ducts inside and outside the liver, a distended gallbladder, and no stone or pancreatic mass.

Where is each block, and what comes next?

Illustrative patients, not real ones.

CHOLANGIOCARCINOMA

2

What and where

Slide 3: What and where
03 / 56

What and where

PART 1

CHOLANGIOCARCINOMA

3

Slide 4: A cancer of the bile duct lining
04 / 56

A cancer of the bile duct lining

WHAT AND WHERE

Cholangiocarcinoma under the microscope: atypical bile duct-like cells in abundant fibrous stroma (haematoxylin and eosin stain).

Nephron, CC BY-SA 3.0, via Wikimedia Commons.

A malignancy arising from the lining of the bile ducts, anywhere along the biliary tree.

Over 95% are ductal adenocarcinomas.

How common, at what age, which sex: by book

Bailey

1⁠–⁠1.5 per 100 000 a year; a peak in the eighth decade; men to women about 1.5 to 1.

Schwartz

About 1 per 100 000 a year in the United States; a slight male predominance; an average age at presentation of 50⁠–⁠70.

CHOLANGIOCARCINOMA

4

Slide 5: Three sites
05 / 56

Three sites

WHAT AND WHERE

Intrahepatic: inside the liver.

Perihilar (hilar): at the junction of the right and left ducts; the Klatskin tumour.

Distal: the lower bile duct.

How the share splits: the books differ

Bailey: hilar 60%, distal 20⁠–⁠30%, intrahepatic 10⁠–⁠20%.

Schwartz: about half at the bifurcation, 40% more distal, 10% intrahepatic.

Sabiston: more than two thirds near the bifurcation.

CHOLANGIOCARCINOMA

5

Slide 6: Most have no known risk factor
06 / 56

Most have no known risk factor

WHAT AND WHERE

Recap: PSC, Lecture 8

Most patients have no known risk factor.

In the West, the main one is primary sclerosing cholangitis (PSC).

PSC's cancer risk: the books use different time scales

Sabiston: 1.5% a year.

Schwartz: a 5⁠–⁠10% lifetime risk.

Schwartz, elsewhere: 10⁠–⁠15% will develop it.

CHOLANGIOCARCINOMA

6

Slide 7: Other risks, as the books print them
07 / 56

Other risks, as the books print them

WHAT AND WHERE

The ducts: choledochal cysts and Caroli disease; stones inside the liver (hepatolithiasis); recurrent pyogenic cholangitis (oriental cholangiohepatitis); biliary⁠–⁠enteric anastomoses.

Infection: liver flukes (Clonorchis sinensis, Opisthorchis viverrini); chronic typhoid carriage; hepatitis B or C.

Others: ulcerative colitis; non-alcoholic fatty liver disease; cirrhosis; chemicals: Thorotrast, vinyl chloride, dioxin, asbestos, cigarette smoke.

Recap, Lecture 8

Choledochal cyst

Caroli disease

Recurrent pyogenic cholangitis

Liver flukes

CHOLANGIOCARCINOMA

7

Slide 8: Cancer in PSC
08 / 56

Cancer in PSC

WHAT AND WHERE

Recap: PSC, Lecture 8

Earlier, at 30⁠–⁠50 years.

Usually multifocal.

Found at an advanced stage, with a poorer outlook.

It can occur at any time, whatever the extent of the PSC.

CHOLANGIOCARCINOMA

8

How it grows

Slide 9: How it grows
09 / 56

How it grows

PART 2

CHOLANGIOCARCINOMA

9

Slide 10: It spreads under the lining
10 / 56

It spreads under the lining

HOW IT GROWS

It tends to spread under the lining (submucosally), and along the nerves (perineural invasion).

So the upper duct margin of a distal tumour is checked by frozen section (slide 40).

Constant pain at presentation suggests more advanced disease.

CHOLANGIOCARCINOMA

10

Slide 11: Its types: the books name them differently
11 / 56

Its types: the books name them differently

HOW IT GROWS

Bailey

28th edition

Three histological types: mass forming, intraductal growing, periductal infiltrating.

Sabiston

Sclerosing, nodular, papillary. Sclerosing tumours tend to be proximal, with fibrosis around the duct and a ring-like narrowing.

Schwartz

Nodular (the commonest), scirrhous, diffusely infiltrating, papillary.

CHOLANGIOCARCINOMA

11

How it presents

Slide 12: How it presents
12 / 56

How it presents

PART 3

CHOLANGIOCARCINOMA

12

Slide 13: Painless jaundice
13 / 56

Painless jaundice

HOW IT PRESENTS

Is jaundice the first sign? The books disagree

Schwartz

Painless jaundice is the commonest first presentation; itching, mild right upper abdominal pain, loss of appetite, tiredness and weight loss may also be present.

Bailey

Early symptoms are often non-specific (abdominal pain, early fullness, loss of appetite, weight loss); itching and jaundice may be present in a minority.

Cholangitis is the presenting symptom in about 10%.

CHOLANGIOCARCINOMA

13

Slide 14: Painless jaundice: with the block
14 / 56

Painless jaundice: with the block

HOW IT PRESENTS

Recap: a block after the liver, Lecture 2

With the block: itching, dark urine, pale (clay-coloured) stools, steatorrhoea.

CHOLANGIOCARCINOMA

14

Slide 15: Inside the liver: a mass more than jaundice
15 / 56

Inside the liver: a mass more than jaundice

HOW IT PRESENTS

Much less likely to present with jaundice.

There may be dull right upper abdominal pain, fever or weight loss, and a raised alkaline phosphatase.

It may be found by chance while abnormal liver tests are worked up.

It may present later.

CHOLANGIOCARCINOMA

15

Slide 16: A mass in the liver on imaging
16 / 56

A mass in the liver on imaging

HOW IT PRESENTS

Cholangiocarcinoma on CT: a mass in the liver (outlined).

Samir (English Wikipedia), CC BY-SA 3.0, via Wikimedia Commons.

On CT (computed tomography) or MRI (magnetic resonance imaging): a mass in the liver.

CHOLANGIOCARCINOMA

16

Slide 17: The gallbladder tells the level
17 / 56

The gallbladder tells the level

HOW IT PRESENTS

A hilar block: the ducts inside the liver dilate; the gallbladder and the duct below the tumour are usually normal or collapsed.

A distal block: the ducts inside and outside the liver dilate, and so does the gallbladder; it may be felt.

CHOLANGIOCARCINOMA

17

Slide 18: A gallbladder you can feel
18 / 56

A gallbladder you can feel

HOW IT PRESENTS

Recap: Courvoisier's law, Lecture 2

In a jaundiced patient, a gallbladder you can feel is unlikely to be due to gallstones; it usually means a block low in the duct by a periampullary cancer.

A duct blocked by a stone seldom distends the gallbladder: it is likely to be chronically inflamed.

Periampullary: a cancer of the bile duct, the pancreas or the ampulla.

CHOLANGIOCARCINOMA

18

Investigation

Slide 19: Investigation
19 / 56

Investigation

PART 4

CHOLANGIOCARCINOMA

19

Slide 20: Ultrasound first
20 / 56

Ultrasound first

INVESTIGATION

Lecture 2: the tools

Ultrasound comes first: it shows dilated ducts and the level of the block.

For this cancer, how much it shows: the books differ

Sabiston

It may show dilated ducts inside the liver, but does not usually show the site of the block.

Schwartz

The first test is ultrasound or CT; the tumour itself is usually hard to see on ultrasound, CT or even MRCP (magnetic resonance cholangiopancreatography).

Reading the pattern

Dilated ducts in both lobes suggest a hilar tumour.

Dilated ducts inside and outside the liver, with no pancreatic head mass or stones, suggest a distal cholangiocarcinoma.

CHOLANGIOCARCINOMA

20

Slide 21: CT and MRCP: the extent and the vessels
21 / 56

CT and MRCP: the extent and the vessels

INVESTIGATION

A Klatskin tumour at ERC (endoscopic retrograde cholangiography): no contrast where the ducts join; a wire in each side, ready for drainage stents. The image's left is the patient's left.

Hellerhoff, CC BY-SA 3.0, via Wikimedia Commons.

Triphasic CT: spread, and where the tumour lies against the vessels: can it come out?

MRCP, PTC (percutaneous transhepatic cholangiography) or ERCP (endoscopic retrograde cholangiopancreatography): how far up the ducts it reaches.

A chest CT for staging.

PET (positron emission tomography): for nodes and distant spread; of little help in judging whether it can be removed.

CT and MRCP first; then ERCP or PTC.

CHOLANGIOCARCINOMA

21

Slide 22: One lobe shrinks, the other grows
22 / 56

One lobe shrinks, the other grows

INVESTIGATION

A block of one lobe's duct may shrink that lobe (atrophy), while the other lobe grows.

Atrophy of one lobe, with spread into the other side's portal vein or ducts, is on the list of contraindications to resection (slide 31).

CHOLANGIOCARCINOMA

22

Slide 23: Markers: the books disagree
23 / 56

Markers: the books disagree

INVESTIGATION

As Lecture 8

Bailey

CA 19-9, a tumour marker, may be raised.

Sabiston

CEA (carcinoembryonic antigen) and CA 19-9 are unreliable for diagnosis; if raised, they may help to watch for recurrence.

Schwartz

Above 129 U/mL, sensitivity 79% and specificity 98%; mild rises with cholangitis, biliary obstruction and other gut and gynaecological cancers.

Clinical Algorithms

A baseline CA 19-9 and CEA; neither sensitive nor specific for diagnosis.

CHOLANGIOCARCINOMA

23

Slide 24: Sampling often misses it
24 / 56

Sampling often misses it

INVESTIGATION

Lecture 8, slide 9

ERCP or PTC: the level, a biopsy, and a stent for drainage.

How often sampling misses: each figure measures something different

Schwartz

Fine-needle aspiration and brushings: sensitivity 15⁠–⁠60%.

Bailey

Biopsy non-diagnostic in 40⁠–⁠80%.

EUS (endoscopic ultrasound) can take a needle sample of the tumour or the nodes.

CHOLANGIOCARCINOMA

24

Slide 25: No tissue needed before resection
25 / 56

No tissue needed before resection

INVESTIGATION

Looks resectable, fit for surgery

Explore on the imaging and the suspicion.

Not a surgical candidate

Tissue diagnosis, then palliation.

A possible transplant candidate: ask the transplant team before percutaneous drainage, a biopsy or an EUS needle; each can count against a transplant.

A negative cytology does not exclude cancer.

CHOLANGIOCARCINOMA

25

Slide 26: 7% to 15%
26 / 56

7% to 15%

INVESTIGATION

Not every ‘cancer’ is cancer

Recap: IgG4 disease, Lecture 8

of patients resected for a suspected biliary cancer prove to have benign disease.

One mimic: IgG4 (immunoglobulin G4) disease.

CHOLANGIOCARCINOMA

26

Slide 27: A mass in the liver: is it this cancer?
27 / 56

A mass in the liver: is it this cancer?

INVESTIGATION

1

AFP (alpha-fetoprotein): a raised level suggests hepatocellular carcinoma.

2

Upper endoscopy and colonoscopy: to exclude a metastasis from another primary.

3

A chest CT for staging.

CHOLANGIOCARCINOMA

27

Staging and resectability

Slide 28: Staging and resectability
28 / 56

Staging and resectability

PART 5

CHOLANGIOCARCINOMA

28

Slide 29: How far up the ducts it reaches
29 / 56

How far up the ducts it reaches

BISMUTH⁠–⁠CORLETTE, AS SCHWARTZ DESCRIBES IT

I

The common hepatic duct only.

II

The junction, not the secondary ducts.

IIIa

Into the right secondary ducts.

IIIb

Into the left.

IV

Into both right and left secondary ducts.

Hilar resection is planned on it.

CHOLANGIOCARCINOMA

29

Slide 30: Each site has its own TNM
30 / 56

Each site has its own TNM

AJCC 8TH EDITION, AS PRINTED IN SABISTON

AJCC: American Joint Committee on Cancer. TNM: tumour, node, metastasis.

Intrahepatic, perihilar and distal tumours each have their own table.

T1: under 5 mm into the wall.

T2: 5⁠–⁠12 mm.

T3: over 12 mm.

T4: the coeliac axis, superior mesenteric artery or common hepatic artery.

N1: one to three regional nodes.

N2: four or more.

M1: distant metastasis.

These depths are for distal tumours only.

CHOLANGIOCARCINOMA

30

Slide 31: What stops a resection at the hilum
31 / 56

What stops a resection at the hilum

STAGING AND RESECTABILITY

Contraindications (Sabiston)

Metastases in both lobes, or any disease outside the liver.

The secondary ducts involved on both sides.

The main portal vein encased.

The lobar arteries involved on both sides.

Atrophy of one lobe with the other side's portal vein or ducts involved.

How absolute? The books differ

Sabiston: complex vascular resection and reconstruction for types III and IV.

Schwartz: type IV often considered unresectable, or treatable only by transplantation.

Clinical Algorithms: main portal vein, hepatic artery or nearby organs a relative contraindication; distant liver metastases or disseminated disease rule it out.

One lobe's vessels involved: that lobe comes out with the tumour.

The patient counts too: other illnesses, chronic liver disease.

CHOLANGIOCARCINOMA

31

Slide 32: Enough liver must remain
32 / 56

Enough liver must remain

STAGING AND RESECTABILITY

Can it come out? The vessels, the volume of liver that will remain, its growth after portal vein embolisation (Lecture 11), and metastases.

Not enough liver left: an intrahepatic tumour cannot be removed.

Draining the blocked segments that will stay can help them grow after the resection, at the cost of more infection.

CHOLANGIOCARCINOMA

32

Slide 33: Laparoscopy first
33 / 56

Laparoscopy first

STAGING AND RESECTABILITY

Imaging: looks resectable

Laparoscopy first

No spread: go on to resect.

It spares laparotomies that cannot help.

Before a transplant too.

More than half of patients explored have peritoneal, nodal or liver spread, or locally advanced disease, that rules out resection.

CHOLANGIOCARCINOMA

33

Treatment

Slide 34: Treatment
34 / 56

Treatment

PART 6

CHOLANGIOCARCINOMA

34

Slide 35: 10⁠–⁠15%
35 / 56

10⁠–⁠15%

TREATMENT

Resection: the only chance of cure

Complete removal with clear margins (R0) is the only chance of cure.

Most with perihilar cancer present with advanced disease that cannot be removed.

How many can be removed? Bailey gives two figures

suitable for resection

its text

Under 10%

complete excision possible

its summary box

A multidisciplinary approach is required.

CHOLANGIOCARCINOMA

35

Slide 36: Intrahepatic: a liver resection
36 / 56

Intrahepatic: a liver resection

TREATMENT

A liver resection with clear margins.

Not enough liver left: it cannot come out.

Removing the nodes: no evidence it improves survival; it can be considered for what it tells about the outlook.

CHOLANGIOCARCINOMA

36

Slide 37: Perihilar: the duct and the liver together
37 / 56

Perihilar: the duct and the liver together

TREATMENT

The involved ducts, usually with a liver resection, in one piece.

Bailey 28th edition: a standard or extended liver resection with the caudate lobe, the nodes in one piece, and reconstruction of the biliary tree.

The more liver removed to clear the margins, the better the long-term survival has been.

Routine removal of the nodes: debated, with no shown benefit, though the nodes are among the most important guides to the outlook.

CHOLANGIOCARCINOMA

37

Slide 38: Local excision: the books disagree
38 / 56

Local excision: the books disagree

TREATMENT

Bailey

Local resection should be avoided.

Schwartz

Types I and II without vessel involvement can have local excision with the portal nodes, cholecystectomy, bile duct excision and Roux-en-Y hepaticojejunostomies to both sides. Types IIIa and IIIb add a right or left hepatic lobectomy, often with the caudate.

Sabiston

Type II may need a partial liver resection, commonly with the caudate.

CHOLANGIOCARCINOMA

38

Slide 39: Drain before a major resection?
39 / 56

Drain before a major resection?

TREATMENT

The books advise for different settings

Bailey

28th edition: before an expected major liver resection

Drain, because a bilirubin over 6 mg/dL may impair the liver's regeneration, despite more infection after stenting.

Sabiston

At the hilum

Draining the blocked segments that will stay can help them grow after the resection, but may add infection.

Sabiston

A distal tumour

Drainage raises infection after resection, but is generally useful with a bilirubin over 10 mg/dL or a long wait.

CHOLANGIOCARCINOMA

39

Slide 40: Distal: pancreaticoduodenectomy
40 / 56

Distal: pancreaticoduodenectomy

TREATMENT

A distal tumour may need a pancreaticoduodenectomy (Whipple operation).

Distal tumours are often resectable.

The upper duct margin goes for frozen section: the tumour can grow under the lining.

CHOLANGIOCARCINOMA

40

Slide 41: Transplant: the books disagree
41 / 56

Transplant: the books disagree

TREATMENT

Bailey

In selected patients with locally unresectable disease and no distant spread, often after chemoradiation and laparoscopy; controversial; specialised centres (the Mayo protocol).

Sabiston

Still experimental; for research protocols only.

Schwartz

The best outcomes in perihilar disease, after chemoradiation; very strict criteria, few qualify.

Clinical Algorithms

Promise in highly selected hilar patients.

Results: different measures

Sabiston: up to 70% alive at 5 years in some centres (limited hilar disease with PSC).

Schwartz: 5-year disease-free survival as high as 68%.

CHOLANGIOCARCINOMA

41

Slide 42: After resection: the books differ
42 / 56

After resection: the books differ

TREATMENT

Bailey

A limited role, no survival benefit shown; positive margins or nodes may benefit: refer to an oncologist.

Sabiston

Neither chemotherapy nor radiotherapy used routinely; chemoradiation should be limited to nodal disease, an R1 resection (margins not clear) or a trial.

Schwartz

No proven role for adjuvant chemotherapy; adjuvant radiotherapy has not improved quality of life or survival.

Clinical Algorithms

A modest benefit in phase II trials.

CHOLANGIOCARCINOMA

42

Slide 43: Survival after resection
43 / 56

Survival after resection

TREATMENT

At 5 years, by book

Bailey

About 35%.

Sabiston

20⁠–⁠45% in most series (duct resection with partial hepatectomy); up to 59% in selected proximal series; distal, node-negative and R0: up to 50%.

Schwartz

Perihilar 10⁠–⁠30%, up to 40% with clear margins; distal 30⁠–⁠50%, median 32⁠–⁠38 months.

What predicts the outcome: the T stage, the nodes and the margins; also invasion of nerves and vessels, a non-papillary type and poor differentiation (Bailey 28th edition).

CHOLANGIOCARCINOMA

43

Slide 44: Where it comes back
44 / 56

Where it comes back

TREATMENT

Positive margins and positive nodes carry the greatest risk.

Recurrent disease is palliated, not operated on again.

Regular surveillance after the operation.

A raised marker may help to watch for recurrence.

CHOLANGIOCARCINOMA

44

Palliation

Slide 45: Palliation
45 / 56

Palliation

PART 7

CHOLANGIOCARCINOMA

45

Slide 46: 5 to 8 months
46 / 56

5 to 8 months

PALLIATION

Most need palliation

The majority receive palliative care only.

The aims: relieve the symptoms (jaundice, itching, pain, a blocked duodenum), and prevent liver failure and cholangitis.

Without resection, median survival.

CHOLANGIOCARCINOMA

46

Slide 47: Endoscopic or through the liver
47 / 56

Endoscopic or through the liver

PALLIATION

Distal: ERCP, a stent from the duodenum.

Proximal (hilar): PTC, a drain through the liver; for very high blocks, drains through the liver may be needed to drain fully.

The choice also depends on what is available locally.

CHOLANGIOCARCINOMA

47

Slide 48: Which stent, which segments
48 / 56

Which stent, which segments

PALLIATION

A metal mesh stent in the bile duct, for a Klatskin tumour, on X-ray.

Jmarchn, CC0, via Wikimedia Commons.

A self-expanding metal stent lasts; a plastic stent may need changing or more stents.

Draining a shrunken (atrophic) lobe with stents does not improve palliation.

ERCP can carry bowel bacteria into an undrained part of the tree and cause cholangitis.

CHOLANGIOCARCINOMA

48

Slide 49: Beyond the stent
49 / 56

Beyond the stent

PALLIATION

Chemotherapy: the books disagree

Sabiston

Not shown to improve survival.

Schwartz

Can be offered; low response rates (10⁠–⁠20%), marginal survival benefit.

Bailey

Most with unresectable disease are candidates for palliative chemotherapy.

Photodynamic therapy has been proposed for unresectable disease.

Unresectable intrahepatic tumours: ablation, or transarterial chemoembolisation (TACE), can be considered.

Surgical bypass: rarely; for a distal tumour found unresectable at operation.

CHOLANGIOCARCINOMA

49

Early detection

Slide 50: Early detection
50 / 56

Early detection

PART 8

Recap: PSC, Lecture 8

CHOLANGIOCARCINOMA

50

Slide 51: Watching PSC
51 / 56

Watching PSC

EARLY DETECTION

As Lecture 8

In PSC, screening for bile duct and gallbladder cancer is critical.

How: the books disagree

Sabiston

MRCP for diagnosis and surveillance; ERCP kept for dominant strictures and to exclude cancer.

Schwartz

Serial ERCP and liver biopsies.

Telling a PSC stricture from cancer can be challenging: keep a high index of suspicion, especially when the patient worsens without reason.

It can occur at any time.

CHOLANGIOCARCINOMA

51

Case recap and take-home

Slide 52: Back to the two patients
52 / 56

Back to the two patients

BACK TO THE TWO PATIENTS

Patient A

A hilar block. CT and MRCP for its extent and the vessels; the Bismuth⁠–⁠Corlette type plans the operation. If it cannot be removed: drain it, by PTC for a high block.

Patient B

A distal block: a distal cholangiocarcinoma, among the periampullary cancers. A pancreaticoduodenectomy if it can come out; ERCP and a stent if not.

Illustrative patients, not real ones.

CHOLANGIOCARCINOMA

52

Slide 53: Cholangiocarcinoma in eight lines
53 / 56

Cholangiocarcinoma in eight lines

A VIVA ANSWER

1

What: a cancer of the bile duct lining; over 95% adenocarcinomas; intrahepatic, perihilar or distal.

2

Risk: most have none known; PSC in the West; choledochal cysts, stones in the liver, flukes.

3

Growth: tends to spread under the lining and along the nerves.

4

Presentation: painless jaundice; a hilar block usually leaves the gallbladder normal or collapsed, a distal one distends it.

5

Investigation: ultrasound, then CT and MRCP; a negative brushing does not exclude it; no tissue needed before resection.

6

Staging: Bismuth⁠–⁠Corlette at the hilum; TNM by site; can enough liver remain? Laparoscopy first.

7

Treatment: R0 resection, the only chance of cure, by site: a liver resection; the involved ducts, usually with a liver resection; or a pancreaticoduodenectomy.

8

Palliation: drain the jaundice, ERCP low, PTC high; median 5 to 8 months without resection.

CHOLANGIOCARCINOMA

53

Slide 54: Take home
54 / 56

Take home

TAKE HOME

1

Most have no known risk factor; in the West, PSC is the main one.

2

A hilar block usually leaves the gallbladder normal or collapsed; a distal block distends it.

3

A negative brushing does not exclude cancer.

4

Bismuth⁠–⁠Corlette says how far up the ducts it reaches.

5

Complete removal with clear margins is the only chance of cure.

6

If it cannot come out: drain it, ERCP for low blocks, PTC for high ones.

CHOLANGIOCARCINOMA

54

Sources and image credits

Slide 55: Books used
55 / 56

Books used

REFERENCES

Bailey & Love's Short Practice of Surgery, 28th edition. Chapter 71. 27th edition: pages 1194 and 1205⁠–⁠1209.

Sabiston Textbook of Surgery, 21st edition. Chapter 55.

Schwartz's Principles of Surgery, 11th edition. Chapter 32.

Clinical Algorithms in General Surgery (Docimo and Pauli, editors). Pages 361⁠–⁠363.

Complications in Surgery, 2nd edition. Pages 426 and 446.

CHOLANGIOCARCINOMA

55

Slide 56: Image credits
56 / 56

Image credits

REFERENCES

Diagrams: original drawings for this course (the recaps from Lectures 2 and 8 are labelled). Images: Wikimedia Commons, page commons.wikimedia.org/wiki/File: plus the name; licences at creativecommons.org/licenses.

CHOLANGIOCARCINOMA

56

SlideFile on Wikimedia CommonsAuthor, licence
4Cholangiocarcinoma - high mag.jpgNephron, CC BY-SA 3.0
16CT cholangioca-mark.jpgSamir (English Wikipedia), CC BY-SA 3.0
21Klatskintumor-ERC.jpgHellerhoff, CC BY-SA 3.0
48Choledochal stent, X-ray.jpgJmarchn, CC0

Sources and image credits

Sources and image credits are reproduced from the designated slides.

Images

Sources

  • [1] REFERENCES
  • [2] Books used
  • [3] Bailey & Love's Short Practice of Surgery, 28th edition. Chapter 71. 27th edition: pages 1194 and 1205⁠–⁠1209.
  • [4] Sabiston Textbook of Surgery, 21st edition. Chapter 55.
  • [5] Schwartz's Principles of Surgery, 11th edition. Chapter 32.
  • [6] Clinical Algorithms in General Surgery (Docimo and Pauli, editors). Pages 361⁠–⁠363.
  • [7] Complications in Surgery, 2nd edition. Pages 426 and 446.